The 4R-tauopathies represent a group of neurodegenerative disorders characterized by the predominant accumulation of 4-repeat (4R) tau isoforms in the brain. These diseases—Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and Frontotemporal Dementia with Parkinsonism Linked to Chromosome 17 (FTD-17)—share common mechanistic features but exhibit distinct patterns of cellular vulnerability. Understanding these patterns provides critical insights into disease pathogenesis, clinical heterogeneity, and therapeutic targeting.
This page provides a comprehensive cross-disease comparison of cell-type vulnerability patterns, examining how different neuronal and glial populations are selectively affected in each 4R-tauopathy.
The following Mermaid diagram summarizes the key cellular pathological features across the five 4R-tauopathies:
| Cell Type | PSP | CBD | AGD | GGT | FTD-17 |
|---|---|---|---|---|---|
| Neuronal NFTs | ++ | ++ | + | + | +++ |
| Ballooned Neurons | - | +++ | - | - | - |
| Argyrophilic Grains | - | - | +++ | - | - |
| Tufted Astrocytes | +++ | - | - | - | - |
| Astrocytic Plaques | - | +++ | - | - | - |
| Globular GAIs | - | - | - | +++ | - |
| Coiled Bodies | ++ | +++ | ++ | - | ++ |
| Globular GOIs | - | - | - | +++ | - |
| Motor Neuron Involvement | Rare | Rare | No | Common | Rare |
Legend: - absent, + mild, ++ moderate, +++ prominent
Cortical pyramidal neurons, particularly those in layer V, show differential vulnerability across the 4R-tauopathies:
CBD: Layer V pyramidal neurons exhibit particular susceptibility, forming ballooned achromatic neurons—a hallmark pathological feature[1]. These swollen neurons display reduced staining (achromasia) due to accumulated neurofilaments.
FTD-17: Significant neuronal loss in frontal and temporal cortices with abundant neurofibrillary tangles in cortical neurons[2].
PSP: Moderate neuronal involvement with NFTs primarily in brainstem nuclei rather than cortical neurons.
GGT: Moderate neuronal tau inclusions including pretangles and Pick body-like structures, though less prominent than glial pathology.
AGD: Neuronal pretangles and argyrophilic grains in dendritic processes represent early-stage neuronal involvement.
PSP: Severe involvement of brainstem nuclei including the substantia nigra pars compacta, oculomotor nucleus (explaining vertical gaze palsy), and red nucleus. Neurofibrillary tangles accumulate prominently in these regions.
CBD: Substantia nigra pars compacta shows variable dopaminergic neuron loss, contributing to parkinsonian features.
GGT: Motor cortex and brainstem motor nuclei involvement (Type II/III) leads to upper and lower motor neuron signs resembling ALS.
PSP: Moderate loss of dopaminergic neurons in the substantia nigra pars compacta, contributing to parkinsonism but typically less severe than in Parkinson's Disease.
CBD: Variable loss of dopaminergic neurons in the substantia nigra.
FTD-17: Nigrostriatal involvement present but variable.
GGT: When motor neuron phenotype is present, bulbar motor neurons show vulnerability.
Astrocytic inclusions represent key distinguishing features among 4R-tauopathies:
Tufted astrocytes are the hallmark astrocytic lesion in PSP[3]. These are characterized by:
Astrocytic plaques are the defining astrocytic lesion in CBD[4]:
GGT is characterized by globular astroglial inclusions (GAIs)[5]:
FTD-17 shows thorn-shaped astrocytes in affected regions:
The differential astrocytic vulnerability may relate to:
Oligodendrocyte involvement varies significantly across 4R-tauopathies:
Coiled bodies are present in multiple 4R-tauopathies[6]:
Coiled bodies represent tau-positive inclusions within oligodendrocyte cytoplasm, associated with myelin degeneration and white matter pathology.
GOIs are the defining pathological feature of GGT[7]:
The predominance of GOIs over neuronal pathology distinguishes GGT from other 4R-tauopathies and suggests a primary oligodendrogliopathy.
| Disease | White Matter Pathology | Correlation with Clinical Phenotype |
|---|---|---|
| GGT | Severe, with abundant GOIs | Motor cortex involvement correlates with ALS-like phenotype |
| CBD | Moderate to severe | Correlates with clinical disability |
| PSP | Moderate | Contributes to gait impairment |
| AGD | Mild to moderate | Less clinically significant |
| FTD-17 | Variable | Variable correlation |
Microglial activation is a consistent feature across all 4R-tauopathies:
GGT stands out among 4R-tauopathies for prominent motor neuron involvement:
Clinical features include:
The MAPT H1 haplotype is the primary genetic risk factor for PSP and CBD, but specific variants may influence cell-type vulnerability:
Different cell types may have varying baseline expression of tau isoforms:
Tau pathology may spread via prion-like mechanisms[11]:
High-energy-demand neurons (cortical pyramidal neurons, dopaminergic neurons) show particular vulnerability:
Oligodendrocyte dysfunction may initiate neuronal damage:
The pattern of cell-type vulnerability correlates with clinical phenotype:
| Clinical Feature | Primary Cell Type Involved | Diseases |
|---|---|---|
| Vertical gaze palsy | Brainstem neurons (oculomotor) | PSP |
| Parkinsonism | Substantia nigra dopaminergic neurons | PSP, CBD, FTD-17 |
| Cortical dysfunction | Layer V pyramidal neurons | CBD, FTD-17, GGT |
| Motor neuron disease | Upper/lower motor neurons | GGT |
| Ataxia | Cerebellar neurons | PSP-C |
| Behavioral changes | Frontal cortical neurons | FTD-17, GGT |
Understanding cell-type vulnerability has therapeutic implications:
Dickson DW, et al. Neuropathology of Corticobasal Degeneration (2000). 2000. ↩︎
Ghetti B, et al. Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17 (2022). 2022. ↩︎
Komatsu Y, et al. Tufted Astrocytes in Progressive Supranuclear Palsy (2021). 2021. ↩︎
Liu Y, et al. Astrocytic Plaques and Coiled Bodies in Corticobasal Degeneration (2021). 2021. ↩︎
Ahmed Z, et al. Globular Glial Tauopathies: Consensus Guidelines (2021). 2021. ↩︎
Seitelberger F. Coiled Bodies: History and Significance (2020). 2020. ↩︎
Cai M, et al. Globular Oligodendroglial Inclusions in 4R-Tauopathies (2021). 2021. ↩︎
Hamelin L, et al. Microglial Activation in Corticobasal Degeneration (2020). 2020. ↩︎
Bott NT, et al. GGT Presenting as ALS Phenotype (2021). 2021. ↩︎
Im SY, et al. MOBP and 4R-Tauopathy (2021). 2021. ↩︎
Kaufman SK, et al. Tau Prion-Like Propagation in Neurodegeneration (2021). 2021. ↩︎